biomark
increasingli
utilis
biolog
research
clinic
practic
diagnosi
diseas
monitor
therapeut
prognosi
end
point
clinic
studi
cytokin
small
molecul
orchestr
immun
respons
great
potenti
biomark
human
veterinari
field
given
eas
sampl
blood
high
preval
clinic
applic
focu
protein
detect
area
biomark
discoveri
facilit
new
technolog
develop
digit
elisa
led
signific
increas
sensit
two
highli
relev
exampl
includ
type
interferon
name
directli
quantifi
digit
elisa
biolog
sampl
applic
approach
studi
uniqu
bat
interferon
respons
may
reveal
novel
find
applic
human
veterinari
research
second
exampl
describ
use
diseas
biomark
tuberculosi
highlight
find
human
mous
studi
consid
veterinari
research
summari
describ
cytokin
may
appli
novel
biomark
illustr
two
key
exampl
human
veterinari
research
may
complement
line
one
health
object
blood
plasmaborn
biomark
desir
access
also
offer
potenti
serial
monitor
unlik
snp
static
protein
respons
dynam
therefor
potenti
reflect
diseas
statu
even
respons
therapeut
intervent
plasma
carri
inform
organ
http
doi
biomark
broad
categori
medic
indic
measur
object
determin
differ
medic
state
respons
intervent
therefor
use
basic
diagnosi
therapeut
prognosi
end
point
clinic
studi
examin
biomark
use
research
clinic
human
veterinari
field
inform
field
biomark
may
consist
nucleic
acid
protein
metabolit
even
imag
long
record
measur
consist
object
huge
progress
genom
sinc
success
sequenc
human
genom
much
attent
focus
potenti
use
genet
biomark
howev
despit
dramat
reduct
sequenc
cost
increas
capac
clinic
potenti
approach
still
remain
larg
unmet
uniqu
pharmacogenom
biomark
mani
biomark
multipl
indic
overal
number
higher
current
approv
food
drug
administr
fda
human
treatment
decis
major
genet
marker
singl
nucleotid
polymorph
snp
although
recent
next
gener
sequenc
ng
techniqu
success
appli
particular
cancer
mutat
detect
contrast
use
genet
marker
estim
protein
reliabl
measur
human
plasma
convent
clinic
chemistri
enzymelink
immunosorb
assay
elisa
concentr
rang
protein
estim
current
approv
fda
clinic
biomark
highlight
advanc
matur
technolog
also
potenti
greater
clinic
relev
compar
genet
biomark
addit
estim
secret
protein
present
circul
concentr
less
offer
huge
potenti
new
biomark
discoveri
novel
technolog
digit
elisa
mass
spectometri
base
approach
abil
unlock
potenti
human
veterinari
research
tissu
therefor
analys
plasma
protein
composit
potenti
captur
variat
occur
wide
rang
human
anim
tissu
due
differ
diseas
state
larg
dynam
concentr
rang
plasma
protein
allow
classif
three
main
categori
high
abund
plasma
protein
albumin
mgml
immunoglobulin
protein
mgml
tissu
origin
protein
cytokin
latter
lower
concentr
pgml
particular
interest
immunolog
studi
cytokin
small
signal
molecul
orchestr
immun
respons
enabl
cell
cell
commun
recruit
immun
cell
infect
site
cytokin
subdivid
interleukin
il
interferon
ifn
chemokin
tumor
necrosi
factor
tnf
may
promot
either
proinflammatori
antiinflammatori
respons
capac
stimul
modul
immun
system
therefor
great
indic
normal
immunolog
process
patholog
process
respons
treatment
thu
cytokin
becom
highli
relev
immun
respons
biomark
current
use
wide
rang
clinic
situat
relev
exampl
includ
potenti
diagnost
valu
rheumatoid
psoriat
arthriti
pgml
inflammatori
joint
elev
level
associ
sever
progress
chronic
liver
diseas
pgml
pgml
pgml
respect
cirrhot
liver
cytokin
signatur
base
propos
predict
biomark
glatiram
acet
respons
treatment
multipl
sclerosi
exampl
illustr
cytokin
becom
invalu
biomark
diagnos
diseas
measur
progressionsever
diseas
state
predict
monitor
effect
therapeut
intervent
true
human
immunolog
numer
exampl
also
found
veterinari
medicin
good
illustr
studi
carri
bertuglia
colleagu
kinet
proinflammatori
cytokin
associ
equin
osteoarthr
mean
pgml
synovi
fluid
pgml
serum
furthermor
chang
describ
classic
swine
fever
infect
exampl
peak
day
postinfect
reach
level
pgml
particular
cytokin
profil
associ
natur
african
trypanosom
infect
cattl
mean
pgml
infect
cattl
versu
pgml
uninfect
anim
well
pgml
pgml
infect
uninfect
anim
respect
overal
cytokin
biomark
hold
great
potenti
monitor
health
diseas
state
field
human
anim
medicin
first
cytokin
identifi
descript
solubl
factor
protect
cell
viral
infect
made
isaac
lindenmann
thu
initi
field
research
despit
discoveri
year
ago
direct
measur
type
ifn
protein
biolog
sampl
remain
challeng
type
ifn
mrna
usual
present
trace
level
peripher
blood
mononuclear
cell
pbmc
healthi
individu
current
elisa
prove
either
insensit
unreli
detect
protein
lead
develop
wide
varieti
proxi
assay
type
ifn
signal
low
level
circul
ifn
protein
like
reflect
high
biolog
potenc
type
ifn
cell
type
express
type
ifn
receptor
ifnar
inde
addit
role
antivir
protect
becom
clear
inappropri
excess
exposur
ifn
major
detriment
effect
balanc
must
struck
abil
fight
infect
versu
risk
inflammatori
diseas
latter
point
well
illustr
strong
correl
enhanc
type
ifn
signal
system
lupu
erythematosu
sle
juvenileonset
dermatomyos
jdm
type
interferon
furthermor
human
multipl
speci
type
ifn
exist
heterogen
aris
distinct
encod
gene
includ
function
gene
one
gene
situat
synten
human
chromosom
differ
ifnsubtyp
product
activ
site
profil
allow
subtleti
immun
function
present
poorli
understood
despit
key
role
mani
diseas
studi
type
ifn
protein
level
biolog
sampl
challeng
recent
convent
sandwich
elisa
wide
use
method
detect
protein
howev
despit
specif
simpl
rapid
type
ifn
elisa
assay
present
import
limit
particular
insuffici
sensit
addit
measur
subtyp
requir
use
multipl
assay
detect
capac
sensit
limit
detect
lod
classic
elisa
within
picomolar
rang
insuffici
detect
protein
biolog
sampl
previous
mention
fact
possibl
reflect
biolog
potenc
type
ifn
therebi
highlight
lack
tool
monitor
level
cytokin
infect
autoimmun
overcom
limit
sever
biolog
proxi
assay
develop
quantifi
type
ifn
measur
induc
gene
express
function
activ
nonetheless
import
emphas
assay
provid
direct
measur
protein
howev
recent
develop
digit
elisa
particular
singl
molecul
immunoassay
simoa
repres
signific
advanc
previou
approach
made
possibl
direct
quantif
cytokin
type
ifn
simoa
util
paramagnet
bead
coupl
specif
antibodi
isol
femtolitres
nanowel
specif
design
isol
singl
bead
high
throughput
manner
innov
step
reduc
nonspecif
background
fluoresc
signal
allow
specif
signal
measur
digit
fashion
result
signific
increas
sensit
increas
confid
low
measur
previou
nonspecif
technic
nois
greatli
reduc
applic
approach
quantif
protein
attomolar
concentr
allow
descript
protein
human
plasma
cerebrospin
fluid
csf
cellular
lysat
first
time
divers
diseas
cohort
rang
autoimmun
viral
infect
median
fgml
interquartil
rang
iqr
fgml
plasma
healthi
individu
median
fgml
iqr
fg
ml
plasma
sle
patient
median
fgml
iqr
fgml
plasma
jdm
patient
protein
could
also
detect
csf
patient
central
nervou
system
infect
median
fgml
iqr
fgml
therefor
novel
approach
may
also
appli
veterinari
research
question
specif
antibodi
avail
particular
speci
interest
area
research
approach
could
provid
novel
insight
human
anim
field
immun
respons
bat
viral
infect
bat
recognis
potenti
reservoir
mani
virus
coronavirus
filovirus
lyssavirus
henipavirus
caus
sever
diseas
human
bat
speci
like
result
close
coevolutionari
histori
virus
enabl
live
symbiot
relationship
bat
consid
import
sourc
futur
viral
pandem
outbreak
better
understand
uniqu
scenario
recent
fascin
studi
sequenc
locu
australian
black
fli
fox
pteropu
alecto
studi
identifi
bat
highli
contract
type
ifn
famili
consist
ifn
includ
three
function
loci
comparison
size
locu
differ
anim
reveal
rang
kb
fish
mb
pig
trend
toward
increas
size
evolut
notabl
except
smaller
size
chicken
bat
kb
kb
respect
consist
increas
genom
size
ifn
locu
gene
duplic
also
occur
vertebr
type
ifn
famili
initi
four
type
ifn
fish
pig
specif
speci
bat
notabl
except
fewest
three
differ
anim
studi
loci
bat
speci
highli
similar
share
amino
acid
sequenc
rel
similar
human
protein
amino
acid
similar
includ
predict
signal
peptid
conserv
bind
domain
term
better
understand
antivir
immun
particular
interest
bat
observ
three
gene
constitut
express
healthi
tissu
two
differ
bat
speci
result
induct
subset
ifnstimul
gene
associ
antivir
activ
resist
dna
damag
furthermor
upon
poli
ic
stimul
agonist
transcript
level
chang
contrast
level
show
strong
induct
suggest
distinct
divis
function
differ
type
interferon
speci
challeng
ascertain
far
human
mammal
due
lack
avail
tool
level
protein
quantifi
bat
hypothesis
much
mrna
may
remain
untransl
provid
sourc
transcript
rapid
translat
requir
therefor
quantif
protein
level
may
help
understand
bat
constitut
restrict
virus
without
necessarili
inhibit
replic
crucial
bat
interferon
respons
appear
avoid
much
neg
inflammatori
signal
associ
ifn
respons
human
recent
vitro
analysi
suggest
poli
ic
induc
respons
bat
may
trigger
inflammatori
pathway
author
present
evid
may
occur
uniqu
repressor
crel
bind
motif
promot
present
speci
bat
examin
mammal
better
understand
structur
function
uniqu
speci
signal
pathway
may
lead
develop
novel
cytokin
base
antivir
therapi
wide
use
treatment
chronic
viral
hepat
rel
success
roughli
patient
fail
respond
current
treatment
replac
potent
effect
direct
act
antivir
type
ifn
specif
also
use
therapi
multipl
sclerosi
antiifnar
antibodi
propos
treat
lupu
automimmun
diseas
mix
result
therefor
insight
new
find
uniqu
bat
interferon
respons
could
wide
rang
implic
mani
human
diseas
area
estim
quarter
worldwid
popul
latent
infect
mycobacterium
tuberculosi
tb
caus
agent
human
tuberculosi
tb
develop
activ
tb
diseas
pulmonari
tb
common
manifest
diseas
bodi
site
also
affect
case
extrapulmonari
tb
accord
global
tuberculosi
report
three
main
test
current
exist
diagnos
tb
diseas
smear
microscopi
cultur
method
pcr
molecular
test
exampl
xpert
mtbrif
assay
cepheid
amplifi
genom
dna
bacteria
three
test
base
test
sputum
sampl
challeng
obtain
particularli
children
hivinfect
individu
thu
urgent
unmet
clinic
need
bloodbas
biomark
test
diagnos
patient
activ
tb
diseas
current
two
main
assay
identifi
whether
individu
infect
tb
howev
test
permit
discrimin
latent
infect
activ
tb
diseas
particular
endem
area
mantoux
tuberculin
skin
test
tst
interferongamma
releas
assay
igra
tst
tuberculin
purifi
protein
deriv
ppd
inject
intraderm
wherea
igra
test
blood
incub
ex
vivo
specif
tb
antigen
eg
test
individu
infect
tb
immun
respons
elicit
detect
either
form
skin
reaction
former
detect
secret
antigenspecif
cell
latter
nonetheless
human
speci
suscept
tuberculosi
infect
mycobacterium
bovi
bovi
main
caus
agent
bovin
tuberculosi
target
wide
rang
wild
domest
anim
particular
interest
bovi
infect
cattl
product
econom
reason
well
potenti
zoonosi
impact
public
health
earli
diagnosi
infect
anim
essenti
limit
transmiss
spread
diseas
control
measur
typic
involv
test
slaughter
strategi
situat
complic
fact
bovi
may
sever
anim
reservoir
differ
geograph
set
badger
deer
possum
buffalo
current
absenc
effect
diagnosi
test
multipl
speci
vaccin
make
contain
diseas
extrem
difficult
tool
employ
diagnos
bovin
tuberculosi
summaris
two
main
categori
detect
tcell
specif
immun
respons
tst
igra
well
serolog
test
detect
specif
antibodi
although
current
avail
test
wide
use
play
key
role
manag
tuberculosi
diseas
still
present
import
limit
specif
tst
compromis
potenti
crossreact
environment
mycobacteria
vaccin
bacilli
bcg
implement
almost
year
ago
still
remain
clinic
approv
tb
vaccin
furthermor
human
still
lack
abil
identifi
peopl
greater
risk
develop
activ
tb
diseas
thu
import
challeng
remain
field
tb
diagnost
urgent
need
develop
novel
highli
sensit
bloodbas
test
without
meet
goal
tb
erad
possibl
last
fifteen
year
whole
bloodbas
test
base
measur
becom
essenti
diagnosi
tb
current
two
commerci
igra
avail
quantiferontb
gold
intub
test
qiagen
tspot
tb
test
oxford
immunotec
antigen
choic
potenti
elicit
specif
cell
respons
base
biomark
readout
quantiferon
test
use
convent
elisa
measur
posit
cutoff
valu
iuml
pgml
tspot
tb
test
base
enzymelink
immunospot
elispot
less
spot
nil
control
spot
posit
control
must
obtain
test
valid
test
result
consid
posit
number
spot
obtain
tb
antigen
stimul
number
nil
spot
subtract
higher
research
focus
identif
novel
biomark
aim
provid
increas
diagnost
accuraci
ruhwald
colleagu
review
clinic
studi
proinflammatori
cytokin
ifninduc
protein
ip
chemokin
ligand
cxcl
investig
potenti
surrog
biomark
context
tb
infect
follow
level
mean
rang
obtain
upon
mtb
antigen
stimul
pgml
pgml
control
tb
patient
respect
pgml
pgml
induc
broad
transcript
programm
includ
express
thu
present
biolog
amplif
signal
potenti
increas
robust
sensit
cell
respons
measur
cytokin
produc
larg
quantiti
patient
activ
tb
compar
control
use
biomark
compar
immunolog
microbiolog
infecti
diseas
tb
infect
could
help
overcom
import
limit
igra
test
young
children
immunocompromis
individu
monokinebas
report
shown
sensit
accur
studi
antigenspecif
cell
respons
howev
despit
highli
promis
detect
assay
still
requir
standardis
valid
becom
routin
use
clinic
practic
includ
sampl
process
technolog
platform
clinic
cutoff
valu
posit
similarli
igra
test
also
exist
bovi
bovigam
thermofisch
gold
standard
follow
principl
tb
test
ex
vivo
whole
blood
antigen
stimul
follow
detect
cellmedi
immun
respons
releas
despit
wide
use
sensit
specif
limit
test
base
approach
serolog
enferplex
tb
enfer
scientif
shown
studi
give
better
diagnost
perform
thu
potenti
use
biomark
bovi
order
increas
sensit
convent
igra
aris
attract
altern
although
water
colleagu
perform
studi
show
advantag
use
diagnosi
bovi
recent
find
support
idea
cytokin
sensit
valuabl
biomark
bovi
infect
cattl
buffalo
current
altern
singl
biomark
well
combin
signatur
intens
research
improv
efficaci
tb
diagnost
test
amongst
also
cytokin
explor
addit
complic
use
tb
diseas
biomark
relat
previous
describ
posttransl
modif
human
mous
studi
vitro
studi
shown
ntermin
truncat
proinflammatori
chemokin
lead
gener
antagonist
form
moreov
recent
vivo
work
perform
mice
demonstr
truncat
alter
lymphocyt
migrat
limit
infiltr
tumor
parenchyma
phenomenon
could
revers
use
inhibitor
sitagliptin
human
studi
utilis
immunoassay
discrimin
full
length
agonist
form
refer
long
nh
form
gener
cleavag
refer
short
shown
elev
level
short
associ
increas
activ
neg
predictor
viral
clearanc
chronic
acut
hepat
c
hcv
patient
mean
plasma
concentr
chronic
hcv
patient
pgml
versu
pgml
individu
sustain
virolog
respons
final
vivo
valid
shown
inhibit
activ
sitagliptin
intervent
healthi
donor
chronic
infect
hcv
patient
result
preserv
long
agonist
form
therefor
biomark
studi
reli
either
human
veterinari
studi
consid
posttransl
modifi
isoform
assess
health
diseas
quantif
cytokin
present
plasma
particularli
attract
due
eas
safeti
feasibl
method
well
fact
plasma
reflect
state
anim
human
bodi
particular
time
point
therefor
approach
use
decad
although
progress
made
last
year
surprisingli
modest
possibl
reason
behind
slow
advanc
intrins
complex
biolog
system
inher
interindividu
variabl
addit
complic
use
cytokin
biomark
lie
fact
molecul
short
halflif
circul
often
found
low
concentrationssuch
concentr
fgml
rang
differ
autoimmun
condit
thu
highli
sensit
method
requir
specif
abl
associ
singl
cytokin
measur
particular
diseas
absolut
certainti
extrem
challeng
moreov
account
nondiseas
variat
natur
occur
variabl
among
differ
individu
essenti
tri
defin
refer
interv
establish
boundari
health
aim
improv
signaltonois
context
diseas
diagnosi
two
main
strategi
defin
one
involv
utilis
standardis
approach
studi
induc
immun
approach
second
complementari
approach
compris
use
multipl
cytokin
marker
detect
multiplex
assay
instead
singl
analyt
identif
robust
signatur
addit
studi
defin
genet
environment
contribut
natur
occur
variabl
provid
refer
rang
valu
help
better
identifi
real
biolog
signal
background
nois
asid
pure
scientif
consider
limit
assess
potenti
use
cytokin
biomark
includ
lack
share
central
databas
exist
genet
studi
well
basic
systemat
knowledg
genet
impact
cytokin
variabl
furthermor
protein
measur
remain
expens
mean
larg
reagent
manufactur
innov
requir
assay
becom
part
common
clinic
practic
worldwid
last
least
commerci
consider
includ
intellectu
properti
regulatori
approv
play
key
role
make
cytokin
biomark
test
avail
cytokin
key
player
homeostasi
immun
respons
thu
hold
great
potenti
becom
biomark
diseas
respons
treatment
despit
current
limit
numer
success
exampl
exist
human
veterinari
medicin
cytokin
biomark
help
diagnosi
monitor
wide
rang
diseas
larg
effort
taken
overcom
prevail
challeng
benefit
full
potenti
cytokin
novel
biomark
discoveri
implement
